A newly discovered method for detecting early signs of a common neurodegenerative disease has shown promise in clinical trials, offering potential for earlier intervention. Researchers identified a specific biomarker linked to the condition’s progression, which could enable more precise diagnosis before symptoms become severe. The findings suggest a shift toward personalized treatment approaches, though further validation is needed before widespread adoption. Experts emphasize the need for continued study to confirm its reliability in diverse patient populations.